Clinical Trial Update: Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) [Phase 3]

View source ↗

Summary

Phase 3 results for Perfluorohexylcotane (NOV03) in treating signs and symptoms of dry eye disease associated with Meibomian Gland Dysfunction have been complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Meibomian Gland Dysfunction

Drugs mentioned

• NOV03 (Perfluorohexylcotane) (Perfluorohexylcotane)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Dry Eye Disease (DED) | Phase 3 | Status: COMPLETED | Results posted: 2024-10-23